摘要
目的探索外周T细胞淋巴瘤(PTCL)患者外周血中髓源性抑制细胞(MDSCs)数量与预后的关系。方法收集PTCL患者23例,选取14例同期健康体检者作为正常对照组,采用流式细胞仪检测其外周血MDSCs/单核细胞比例,分析MDSCs数量与PTCL患者预后及临床特征的关系。结果 MDSCs在PTCL患者外周血单核细胞中所占的比例高于正常对照组[(4.59±1.41)%vs(1.36±0.59)%,P<0.01]。PTCL化疗后外周血MDSCs的表达(1.29±2.95)%较化疗前明显降低。结外侵犯部位、骨髓侵犯、临床分期、IPI评分不同的PTCL患者外周血MDSCs的表达差异有统计学意义(P<0.05)。结论 MDSCs在PTCL患者外周血中高表达,提示与肿瘤发生及预后不良有关。
Objective To study the relationship between the number of myeloid-derived suppressor cells (MDSCs) in peripheral blood and prognosis in patients with peripheral T-cell lymphoma (PTCL). Methods Twenty-three patients with PTCL were selected in this study and 14 healthy persons were used as the normal control. The proportion of MDSCs/mononu-clear in peripheral blood was detected by flow cytometry. The correlation between the number of MDSCs and the clinical character and prognosis in patients with PTCL was analyzed. Results The proportion of MDSCs in peripheral blood was sig-nificantly higher in patients with PTCL than that of healthy subjects [(4.59±1.41)%vs (1.36±0.59)%, P〈0.01]. The number of MDSCs in peripheral blood was significantly decreased after chemotherapy compared with that before treatment [( 1.29 ± 2.95)%, P〈0.05)]. There were significant differences in MDSCs expressions in patients between different extranodal involve-ment, bone marrow involvement, clinical stage and IPI score (P〈0.05). Conclusion The higher expression of MDSCs may be related to the progression in patients with PTCL.
出处
《天津医药》
CAS
2015年第3期282-284,共3页
Tianjin Medical Journal
基金
广西自然科学基金青年基金项目(2011GXNSFB018092)
关键词
淋巴瘤
T细胞
外周
流式细胞术
髓源性抑制细胞
lymphoma,T-cell,peripheral
flow cytometry
myeloid-derived suppressor cells